Search Within

Neil Howard Segal

Formats
  1. Meeting Abstract (111)
  2. Journal Article (97)
  3. Review (2)
  4. Book Section (1)
  5. Miscellaneous (1)
  6. Research Letter (1)
Groups
  1. Department of Medicine (213)
  2. Gastrointestinal Oncology Service (213)
  3. Solid Tumor Oncology Division (213)
  4. Center for Pancreatic Cancer Research (98)
  5. Surgery (81)
  6. Survivorship Research (80)

More Groups

People
  1. Leonard Saltz (82)
  2. Andrea Cercek Hanjis (70)
  3. Zsofia Stadler (67)
  4. Martin Weiser (61)
  5. Rona Yaeger (61)
  6. Jinru Shia (56)

More People

Years
  1. 2025 (9)
  2. 2024 (15)
  3. 2023 (12)
  4. 2022 (14)
  5. 2021 (11)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (78)
  2. Annals of Oncology (22)
  3. Clinical Cancer Research (9)
  4. Cancer Research (6)
  5. Journal for ImmunoTherapy of Cancer (6)
  6. Modern Pathology (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (83)
  2. Oxford University Press (27)
  3. American Association for Cancer Research (21)
  4. Elsevier Inc. (19)
  5. Nature Publishing Group (10)
  6. Biomed Central Ltd (6)

More Publishers

Results (213)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterization and clinical outcomes of DNA mismatch repair-deficient small bowel adenocarcinoma
    Journal Article

    Latham, A.; Shia, J.; Patel, Z.; Reidy-Lagunes, D. L.; Segal, N. H.; Yaeger, R.; Ganesh, K.; Connell, L.; Kemeny, N. E.; Kelsen, D. P.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase II study of induction PD-1 blockade in subjects with locally advanced mismatch repair-deficient rectal adenocarcinoma
    Meeting Abstract

    Cercek, A.; Stadler, Z. K.; Cohen, J. L.; Weiss, J. A.; Lamendola-Essel, M. F.; Krishnan, A.; Yaeger, R.; Segal, N. H.; Connell, L. C.; El Dika, I. H.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101)
    Meeting Abstract

    Blumenschein, G. R. Jr; Davar, D.; Gutierrez, R.; Segal, N. H.; Johnson, M. L.; Dar, M. M.; Marshall, S.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase IB/II open-label, randomized evaluation of atezolizumab (atezo) plus selicrelumab (seli) plus gemcitabine plus nab-paclitaxel (gem plus nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC
    Meeting Abstract

    Manji, G.; Bahary, N.; Chung, V.; Dalenc, F.; Ducreux, M.; Gomez-Roca, C.; Im, S. A.; Kortmansky, J.; Lacy, J.; Segal, N.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade
    Journal Article

    Zhang, Q.; Luo, J.; Wu, S.; Si, H.; Gao, C.; Xu, W.; Abdullah, S. E.; Higgs, B. W.; Dennis, P. A.; van der Heijden, M. S.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer
    Journal Article

    Jimenez-Rodriguez, R. M.; Patil, S.; Keshinro, A.; Shia, J.; Vakiani, E.; Stadler, Z.; Segal, N. H.; Yaeger, R.; Konishi, T.; Shimada, Y.; more...
    OncoImmunology (2020)

    Fulltext@MSK | Save
  • Clinical implications of drug-induced liver injury in early-phase oncology clinical trials
    Journal Article

    Mondaca, S. P.; Liu, D.; Flynn, J. R.; Badson, S.; Hamaway, S.; Gounder, M. M.; Khalil, D. N.; Drilon, A. E.; Li, B. T.; Jhaveri, K. L.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy
    Journal Article

    Cercek, A.; Dos Santos Fernandes, G.; Roxburgh, C. S.; Ganesh, K.; Ng, S.; Sanchez-Vega, F.; Yaeger, R.; Segal, N. H.; Reidy-Lagunes, D. L.; Varghese, A. M.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC)
    Meeting Abstract

    Wainberg, Z. A.; Diamond, J. R.; Curigliano, G.; Deva, S.; Bendell, J. C.; Han, S. W.; Kalyan, A.; Naidoo, J.; Kim, R. D.; Patel, S. P.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • PD-1 blockade in advanced adrenocortical carcinoma
    Meeting Abstract

    Raj, N.; Zheng, Y.; Kelly, V.; Katz, S.; Chou, J.; Do, R.; Capanu, M.; Zamarin, D.; Saltz, L.; Ariyan, C.; more...
    Pancreas (2020)

    Fulltext@MSK | Save